<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900133</url>
  </required_header>
  <id_info>
    <org_study_id>CASE7104</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-7104</secondary_id>
    <nct_id>NCT00900133</nct_id>
  </id_info>
  <brief_title>Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer</brief_title>
  <official_title>A Pilot Trial to Correlate Serum Levels of Calgranulin A and B With Estrogen Receptor Status Among Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Measuring levels of calgranulin A and calgranulin B in the blood of patients with
      breast cancer in the laboratory may help doctors identify and learn more about biomarkers
      related to breast cancer.

      PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the
      blood of patients with newly diagnosed stage I, stage II, or stage III breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine circulating levels of calgranulin A and calgranulin B in patients with
           estrogen receptor negative or estrogen receptor positive, newly diagnosed, primary stage
           I-III adenocarcinoma of the breast.

      OUTLINE: This is a pilot study.

      Patients undergo a blood draw following diagnosis of breast cancer to assess levels of
      circulating tumor markers, calgranulin A and calgranulin B. Serum samples are evaluated by
      enzyme-linked immunosorbent assay for tumor marker expression.

      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between circulating levels of calgranulin A and calgranulin B and the presence of estrogen receptor negative breast cancer</measure>
    <time_frame>upon diagnosis</time_frame>
  </primary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
    <description>Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood draw following diagnosis of breast cancer to assess levels of circulating tumor
      markers.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients With Newly Diagnosed Stage I,II,III Breast Cancer. Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary adenocarcinoma of the breast

               -  Stage I-III disease

               -  No evidence of metastatic disease

               -  Newly diagnosed disease

          -  Hormone receptor status:

               -  Estrogen receptor-positive- or -negative tumor

        PATIENT CHARACTERISTICS:

        Sex

          -  Not specified

        Menopausal status

          -  Not specified

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant

          -  No Crohn's disease

          -  No arthritis

          -  No psoriasis

          -  No lupus erythematosus

          -  No multiple sclerosis

          -  No other severe active inflammation

          -  Not C-reactive protein positive

          -  No HIV positivity

          -  No other serious medical or psychiatric illness

        PRIOR CONCURRENT THERAPY:

        Radiotherapy

          -  No prior radiotherapy for breast cancer

        Surgery

          -  No prior organ transplantation

        Other

          -  No prior systemic therapy for breast cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Pink, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <name_title>John Pink, PhD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

